- Home
- CNFR vs APLM Comparison
CNFR vs APLM Comparison
Compare CNFR & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNFR
- APLM
- Stock Information
- Founded
- CNFR 2009
- APLM 2016
- Country
- CNFR United States
- APLM United States
- Employees
- CNFR N/A
- APLM N/A
- Industry
- CNFR Property-Casualty Insurers
- APLM Blank Checks
- Sector
- CNFR Finance
- APLM Finance
- Exchange
- CNFR Nasdaq
- APLM Nasdaq
- Market Cap
- CNFR 7.9M
- APLM 6.9M
- IPO Year
- CNFR 2015
- APLM N/A
- Fundamental
- Price
- CNFR $0.84
- APLM $6.10
- Analyst Decision
- CNFR
- APLM
- Analyst Count
- CNFR 0
- APLM 0
- Target Price
- CNFR N/A
- APLM N/A
- AVG Volume (30 Days)
- CNFR 15.5K
- APLM 10.4K
- Earning Date
- CNFR 05-14-2025
- APLM 04-03-2025
- Dividend Yield
- CNFR N/A
- APLM N/A
- EPS Growth
- CNFR N/A
- APLM N/A
- EPS
- CNFR 1.96
- APLM N/A
- Revenue
- CNFR $64,021,000.00
- APLM $198,000.00
- Revenue This Year
- CNFR $25.91
- APLM $415.15
- Revenue Next Year
- CNFR N/A
- APLM N/A
- P/E Ratio
- CNFR $0.43
- APLM N/A
- Revenue Growth
- CNFR N/A
- APLM N/A
- 52 Week Low
- CNFR $0.42
- APLM $4.47
- 52 Week High
- CNFR $1.91
- APLM $36.14
- Technical
- Relative Strength Index (RSI)
- CNFR 60.78
- APLM 49.61
- Support Level
- CNFR $0.74
- APLM $5.98
- Resistance Level
- CNFR $0.87
- APLM $7.14
- Average True Range (ATR)
- CNFR 0.04
- APLM 0.78
- MACD
- CNFR 0.00
- APLM 0.12
- Stochastic Oscillator
- CNFR 83.10
- APLM 46.31
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.